Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.

This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.

The Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is the only confirmed oncogenic protein.

This article summarized the latest R&D progress of Diflunisal, the Mechanism of Action for Diflunisal, and the drug target R&D trends for Diflunisal.

YS Biopharma Co., Ltd., pledged to discovery, develop, produce, and supply innovative vaccines and therapeutic biologics for infectious illnesses and cancer.

This article summarized the latest R&D progress of Dextromethorphan polistirex, the Mechanism of Action for Dextromethorphan polistirex, and the drug target R&D trends for Dextromethorphan polistirex.

As a functionally diversified transcription factor, STAT3 can interact with a large number of signal molecules and forms various intra- and extracellular signal pathways.

This article summarized the latest R&D progress of Deucravacitinib, the Mechanism of Action for Deucravacitinib, and the drug target R&D trends for Deucravacitinib.

Remegen's Novel Medication Telitacicept (RC18) Achieves Favorable Phase III Outcomes, Applied for a Secondary Use in Managing Rheumatoid Arthritis.

Me-too drugs specifically refer to drugs with their own intellectual property rights, whose efficacy is comparable to that of innovative breakthrough drugs.

This article summarized the latest R&D progress of Deutetrabenazine, the Mechanism of Action for Deutetrabenazine, and the drug target R&D trends for Deutetrabenazine.

Mesentech recently revealed that its Phase 1 trial has begun, and the initial patients have already received their doses of MES1022.